Changes in Bone Mineral Density in Patients with Type 2 Diabetes After Different Bariatric Surgery Procedures and the Role of Gastrointestinal Hormones
- 21 Downloads
To compare changes in bone mineral density (BMD) in patients with morbid obesity and type 2 diabetes (T2D) a year after being randomized to metabolic gastric bypass (mRYGB), sleeve gastrectomy (SG), and greater curvature plication (GCP). We also analyzed the association of gastrointestinal hormones with skeletal metabolism.
Forty-five patients with T2D (mean BMI 39.4 ± 1.9 kg/m2) were randomly assigned to mRYGB, SG, or GCP. Before and 12 months after surgery, anthropometric, body composition, biochemical parameters, fasting plasma glucagon, ghrelin, and PYY as well as GLP-1, GLP-2, and insulin after a standard meal were determined.
After surgery, the decrease at femoral neck (FN) was similar but at lumbar spine (LS), it was greater in the mRYGB group compared with SG and GCP − 7.29 (4.6) vs. − 0.48 (3.9) vs. − 1.2 (2.7)%, p < 0.001. Osteocalcin and alkaline phosphatase increased more after mRYGB. Bone mineral content (BMC) at the LS after surgery correlated with fasting ghrelin (r = − 0.412, p = 0.01) and AUC for GLP-1 (r = − 0.402, p = 0.017). FN BMD at 12 months correlated with post-surgical fasting glucagon (r = 0.498, p = 0.04) and insulin AUC (r = 0.384, p = 0.030) and at LS with the AUC for GLP-1 in the same time period (r = − 0.335, p = 0.049). However, in the multiple regression analysis after adjusting for age, sex, and BMI, the type of surgery (mRYGB) remained the only factor associated with BMD reduction at LS and FN.
mRYGB induces greater deleterious effects on the bone at LS compared with SG and GCP, and gastrointestinal hormones do not play a major role in bone changes.
KeywordsGastrointestinal hormones Bone mineral density Bariatric surgery
The authors thank Dr. Jonathan Rogerson for helpful discussions on the manuscript and Bernat Miguel Huguet for statistical analysis. We thank CERCA Programme Generalitat de Catalunya for institutional support.
Compliance with Ethical Standards
Conflict of Interest
All authors declare that they have no conflict of interest. NV is the recipient of grants “Ajuts per a projectes de recerca clínica de l’Hospital Universitari de Bellvitge (2011-PR143/11)” and of the project “PI11/01960; PI14/01997 and PI17/01556” funded by the Instituto de Salud Carlos III and co-funded by the European Union (ERDF, “A way to build Europe”). JV has funding from the Instituto de Salud Carlos III through the project PI14/00228 and PI17/01503 co-funded by the European Union (ERDF, “A way to build Europe”). SFV has funding from the Spanish Ministry of Economy and Competitiveness and the European Regional Development Fund (ERDF) (SAF2015–65019-R). The Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM) (CB07708/0012) is an initiative of the Instituto de Salud Carlos III. SFV acknowledges support from the Miguel Servet tenure-track program (CP10/00438 and CPII16/0008) from the Fondo de Investigación Sanitaria (FIS) co-financed by the ERDF.
The study was conducted according to the principles of the Declaration of Helsinki.
All patients included in the study signed an informed consent form approved by the institutional ethics committee.
- 1.Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nat Rev Gastroenterol Hepatol. 2017;14(3):160–9.Google Scholar
- 2.Carrasco F, Basfi-Fer K, Rojas P, et al. Changes in bone mineral density after sleeve gastrectomy or gastric bypass: relationships with variations in vitamin D, ghrelin, and adiponectin levels. Obes Surg. 2014;24(6):877–84.Google Scholar
- 3.Muschitz C, Kocijan R, Haschka J, et al. The impact of vitamin D, calcium, protein supplementation, and physical exercise on Bone metabolism after bariatric surgery: the BABS study. J Bone Miner Res. 2016;31(3):672–82.Google Scholar
- 4.Vilarrasa N, de Gordejuela AG, Gómez-Vaquero C, et al. Effect of bariatric surgery on bone mineral density: comparison of gastric bypass and sleeve gastrectomy. Obes Surg. 2013;23(12):2086–91.Google Scholar
- 5.Hsin MC, Huang CK, Tai CM, et al. A case-matched study of the differences in bone mineral density 1 year after 3 different bariatric procedures. Surg Obes Relat Dis. 2015;11(1):181–5.Google Scholar
- 6.Nogués X, Goday A, Peña MJ, et al. Bone mass loss after sleeve gastrectomy: a prospective comparative study with gastric bypass. Cir Esp. 2010;88(2):103–9.Google Scholar
- 7.Maghrabi AH, Wolski K, Abood B, et al. Two-year outcomes on bone density and fracture incidence in patients with T2DM randomized to bariatric surgery versus intensive medical therapy. Obesity (Silver Spring). 2015;23(12):2344–8.Google Scholar
- 8.Napoli N, Chandran M, Pierroz DD, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208–19.Google Scholar
- 9.Stein EM, Silverberg SJ. Bone loss after bariatric surgery: causes, consequences, and management. Lancet Diabetes Endocrinol. 2014;2(2):165–74.Google Scholar
- 10.Hage MP, El-Hajj Fuleihan G. Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass. Osteoporos Int. 2014;25(2):423–39.Google Scholar
- 11.Gagnon C, Schafer AL. Bone health after bariatric surgery. JBMR Plus. 2018;2(3):121–33.Google Scholar
- 12.Wei JH, Lee WJ, Chong K, et al. High incidence of secondary hyperparathyroidism in bariatric patients: comparing different procedures. Obes Surg. 2018;28(3):798–804.Google Scholar
- 13.Mieczkowska A, Irwin N, Flatt PR, et al. Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. Bone. 2013;56(2):337–42.Google Scholar
- 14.Nuche-Berenguer B, Moreno P, Esbrit P, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int. 2009;84(6):453–61.Google Scholar
- 15.Henriksen DB, Alexandersen P, Byrjalsen I, et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone. 2004;34(1):140–7.Google Scholar
- 16.Fukushima N, Hanada R, Teranishi H, et al. Ghrelin directly regulates bone formation. J Bone Miner Res. 2005;20(5):790–8.Google Scholar
- 17.Wong IP, Driessler F, Khor EC, et al. Peptide YY regulates bone remodeling in mice: a link between gut and skeletal biology. PLoS One. 2012;7(7):e40038.Google Scholar
- 18.Casajoana A, Pujol J, Garcia A, et al. Predictive value of gut peptides in T2D remission: randomized controlled trial comparing metabolic gastric bypass, sleeve gastrectomy and greater curvature plication. Obes Surg. 2017;27(9):2235–45.Google Scholar
- 19.Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133–5.Google Scholar
- 20.Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4(6):368–81.Google Scholar
- 21.Wolever TM, Jenkins DJ, Jenkins AL, et al. The glycemic index: methodology and clinical implications. Am J Clin Nutr. 1991;54(5):846–54.Google Scholar
- 22.Crawford MR, Pham N, Khan L, et al. Increased bone turnover in type 2 diabetes patients randomized to bariatric surgery versus medical therapy at 5 years. Endocr Pract. 2018;24(3):256–64.Google Scholar
- 23.Muschitz C, Kocijan R, Marterer C, et al. Sclerotin levels and changes in bone metabolism after bariatric surgery. J Clin Endocrinol Metab. 2015;100(3):891–901.Google Scholar
- 24.Voican CS, Lebrun A, Maitre S, et al. Predictive score of sarcopenia occurrence one year after bariatric surgery in severely obese patients. PLoS One. 2018;13(5):e0197248.Google Scholar
- 25.Brzozowska MM, Sainsbury A, Eisman JA, et al. Bariatric surgery, bone loss, obesity and possible mechanisms. Obes Rev. 2013;14(1):52–67.Google Scholar
- 26.Maccarinelli G, Sibilia V, Torsello A, et al. Ghrelin regulates proliferation and differentiation of osteoblastic cells. J Endocrinol. 2005;184(1):249–56.Google Scholar
- 27.Misra M, Miller KK, Tsai P, et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab. 2006;91(3):1027–33.Google Scholar
- 28.Chan JL, Mun EC, Stoyneva V, et al. Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring). 2006;14(2):194–8.Google Scholar
- 29.Yu EW, Wewalka M, Ding SA, et al. Effects of gastric bypass and gastric banding on bone remodeling in obese patients with type 2 diabetes. J Clin Endocrinol Metab. 2016;101(2):714–22.Google Scholar
- 30.Stern PH, Bell NH. Effects of glucagon on serum calcium in the rat and on bone resorption in tissue culture. Endocrinology. 1970;87(1):111–7.Google Scholar
- 31.Nuche-Berenguer B, Portal-Núñez S, Moreno P, et al. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol. 2010;225(2):585–92.Google Scholar
- 32.Bunck MC, Eliasson B, Cornér A, et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):374–7.Google Scholar
- 33.Karsdal MA, Holst JJ, Henriksen D. GLP-2 reduces bone resorption in vitro via the osteoclast GLP-2 receptor. J Bone Miner Res. 2004;19(S1):S416.Google Scholar
- 34.Vestergaard P. Diabetes and bone fracture: risk factors for old and young. Diabetologia. 2014;57(10):2007–8.Google Scholar
- 35.Walsh JS, Vilaca T. Obesity, type 2 diabetes and bone in adults. Calcif Tissue Int. 2017;100(5):528–35.Google Scholar
- 36.Pittas AG, Harris SS, Eliades M, et al. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab. 2009;94(3):827–32.Google Scholar
- 37.Kanazawa I, Yamaguchi T, Yamauchi M, et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int. 2011;22(1):187–94.Google Scholar
- 38.Ivaska KK, Huovinen V, Soinio M, et al. Changes in bone metabolism after bariatric surgery by gastric bypass or sleeve gastrectomy. Bone. 2017;95:47–54.Google Scholar
- 39.Madsen LR, Espersen R, Ornstrup MJ, et al. Bone health in patients with type 2 diabetes treated by Roux-En-Y gastric bypass and the role of diabetes remission. Obes Surg. 2019;29(6):1823–31.Google Scholar